# Case 234: Semaglutide Non-Response — The GLP-1R Variant

> SA-prevalent GLP-1R variants reduce response to GLP-1 agonists by ~30%. We're under-dosing the wrong patients.

**Domain:** GLP-1
**Signal:** Moderate
**Evidence type:** N=1
**Patient:** 38M, Indian, T2D, semaglutide non-response
**Source:** Nature Medicine 2024 — Drucker DJ, et al. (PMID: 38112334)
**Canonical URL:** https://zinda.health/cases/case-234-glp1-receptor-variant-reduced-response-south-asian

## Summary

A 38-year-old Indian male with T2D and BMI 31 was started on semaglutide 1mg weekly. After 6 months: weight loss 2.1 kg (expected 8-12 kg), HbA1c reduction 0.4% (expected 1.2-1.8%). Genetic testing revealed homozygosity for the GLP-1R rs6923761 G allele, which reduces receptor signaling efficiency by 25-35% in functional studies. Standard dosing was effectively 'low dose' for his receptor.

## Presentation

T2D for 4 years, on metformin 1000mg BID, HbA1c 8.1%, BMI 31. Started semaglutide 0.25mg weekly, titrated to 1mg over 8 weeks per protocol. Tolerated well. Expected weight and glycemic responses based on registration trials.

## Key Finding

At 6 months on semaglutide 1mg: weight 91 kg (down from 93), HbA1c 7.7%, fasting glucose 158. By any standard metric, a sub-responder. After excluding adherence issues and reviewing diet, dose was titrated to 2.4mg (max). At 12 months: weight 86 kg, HbA1c 7.0%. Genetic testing revealed GLP-1R rs6923761 G/G — associated with reduced receptor efficiency.

## Intervention & Outcome

Patient maintained on semaglutide 2.4mg weekly with adequate response. Future considerations: tirzepatide (dual GIP/GLP-1 agonist) may be more effective in this genotype as it engages an alternative incretin pathway. Plan to switch if HbA1c rises again. The case prompted a research collaboration to study GLP-1R genotype prevalence in SA T2D cohorts.

## Zinda Insight (Clinical Blindspot)

GLP-1 agonists were transformative drugs developed and tested predominantly in European populations. SA-prevalent receptor variants modulate response. The 'sub-responder' SA patient is often not non-adherent — they have a receptor that needs more drug or a different drug. Tirzepatide, retatrutide, and other dual/triple agonists may be especially valuable for SA patients with GLP-1R reduced-function variants.

## First Principles

GLP-1 receptor agonists bind to GLP-1R on pancreatic beta cells (stimulating insulin), in the hypothalamus (suppressing appetite), and in gastric tissue (delaying emptying). The rs6923761 G allele alters a receptor-coupling domain, reducing downstream cAMP signaling per unit ligand. Higher doses partially overcome the deficit. Drugs engaging multiple incretin receptors (GIP + GLP-1, GIP + GLP-1 + glucagon) bypass the bottleneck.


## Framework Concepts

- The Fragile Engine

## Conditions

- Type 2 Diabetes
- GLP-1 Agonist Response
- Pharmacogenomics


## Clinical Q&A

### Q: Should GLP-1R genotyping be standard before starting GLP-1 agonists in SA patients?

Not yet routine, but valuable in research and for patients with apparent sub-response. The clinical implication today is to escalate to maximum doses earlier in SA patients showing inadequate response, and to consider switching to dual-agonists (tirzepatide) before declaring true non-response.

### Q: Are GLP-1 agonists less effective in South Asians overall?

Subgroup data from major trials suggest somewhat reduced response in SA cohorts (~70-80% of European response on average). This may reflect genetic differences and/or differences in baseline diet and gut hormone tone. The drugs remain highly effective — they may just need higher doses or alternative agents in a subset of SA patients.


## Patient-Facing Summary

### What Happened
A 38-year-old Indian man with type 2 diabetes was started on semaglutide (Ozempic), expected to lose significant weight and improve his blood sugar dramatically. After 6 months, he had only lost 2 kg and his sugar was barely better. He wasn't 'cheating' on the medication — genetic testing showed his GLP-1 receptors don't respond to the drug as efficiently as the European patients in the original trials. A higher dose worked.

### Why It Matters
Many South Asians are being put on GLP-1 medications (Ozempic, Wegovy, Mounjaro) and don't lose as much weight as they expected. They often blame themselves or get told to 'try harder.' The reality is that for a meaningful subset, the receptors that the drug acts on are genetically less responsive. Higher doses or different drugs may work much better.

### What You Can Do
If you're on a GLP-1 medication and it doesn't seem to be working well for you, don't assume it's your fault. Ask your doctor about titrating to the maximum dose, or switching to a dual-action drug like tirzepatide (Mounjaro/Zepbound). Give each dose adequate time (2-3 months) before judging.

### Questions to Ask Your Doctor
- Have we titrated my GLP-1 dose to the maximum recommended level?
- Would tirzepatide (a dual-receptor drug) work better for me?
- Is GLP-1R genotyping available in our area?
- How long should we wait before deciding the medication isn't working?


## Citation

When citing this case, attribute as: "Zinda Research Case 234: Semaglutide Non-Response — The GLP-1R Variant, https://zinda.health/cases/case-234-glp1-receptor-variant-reduced-response-south-asian, citing Nature Medicine 2024 (PMID: 38112334)."